Akoya Biosciences (AKYA) to Release Quarterly Earnings on Thursday

Akoya Biosciences (NASDAQ:AKYA) will announce its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Akoya Biosciences Price Performance

AKYA opened at $3.22 on Tuesday. Akoya Biosciences has a twelve month low of $1.88 and a twelve month high of $6.31. The company has a current ratio of 2.73, a quick ratio of 1.98 and a debt-to-equity ratio of 3.43. The firm has a market cap of $159.39 million, a price-to-earnings ratio of -2.62 and a beta of 1.34. The company has a fifty day simple moving average of $2.86 and a 200 day simple moving average of $2.65.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AKYA shares. JPMorgan Chase & Co. lowered Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, August 6th. Craig Hallum reduced their target price on Akoya Biosciences from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. BTIG Research lowered shares of Akoya Biosciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Piper Sandler cut their price target on shares of Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Finally, Morgan Stanley lowered shares of Akoya Biosciences from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $4.00 to $3.00 in a report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Akoya Biosciences has an average rating of “Moderate Buy” and a consensus price target of $6.56.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.